烟酰胺在常染色体显性多囊肾病患者中的生物学效应与安全性
本研究通过开放标签单臂试验(N=10)和随机双盲安慰剂对照试验(N=36),评估烟酰胺30 mg/kg口服12个月对ADPKD患者外周血单核细胞中乙酰化p53/总p53比值的影响。结果显示烟酰胺未持续抑制sirtuin活性,身高调整总肾脏体积变化与安慰剂无差异,但安全性和耐受性良好。
要点
- 烟酰胺30 mg/kg口服12个月未持续改变乙酰化p53/总p53比值。
- 烟酰胺与安慰剂相比,身高调整总肾脏体积变化无差异。
- 烟酰胺总体耐受良好,不良事件发生率与安慰剂无差异。
核心结论
- 烟酰胺在ADPKD患者中安全且耐受良好,但未检测到持续抑制sirtuin活性,且无任何疗效指标受益信号。
研究设计与样本
- 研究1为开放标签单臂干预试验,纳入10例ADPKD患者。
- 研究2为随机双盲安慰剂对照试验,纳入36例ADPKD患者。
- 患者接受30 mg/kg口服烟酰胺或安慰剂治疗12个月。
主要发现
- 两项研究中烟酰胺均未对乙酰化/总p53比值产生持续效应,且安慰剂组与烟酰胺组间无差异。
- 烟酰胺组与安慰剂组的身高调整总肾脏体积12个月变化无差异。
- 最常见不良事件为恶心、腹泻、胃食管反流、头痛和痤疮样皮疹,但两组发生率无差异。
关键数值与推荐
- 主要终点为外周血单核细胞中乙酰化p53与总p53蛋白的比值。
临床怎么用
- 烟酰胺30 mg/kg口服12个月在ADPKD患者中安全性良好,但缺乏生物学活性持续抑制及疗效信号,暂不支持其用于ADPKD治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive cyst enlargement, leading to kidney failure. Sirtuin-1 is upregulated in ADPKD and accelerates disease progression by deacetylating p53. Niacinamide is a dietary supplement that inhibits sirtuins at high doses. METHODS: We conducted an open-label, single-arm intervention trial (study 1, N = 10), and a randomized, double blinded, placebo-controlled trial (study 2, N = 36) to assess the biological activity and safety of niacinamide. Patients with ADPKD were given 30 mg/kg oral niacinamide or placebo, for 12 months. The primary endpoint was the ratio of acetylated p53 to total p53 protein in peripheral blood mononuclear cells (PBMCs). RESULTS: There was no sustained effect of niacinamide on acetylated/total p53 in either study and no difference between placebo and niacinamide arms. There was no difference in the change in height-adjusted total kidney volume over 12 months between niacinamide and placebo. Niacinamide was generally well tolerated. The most common adverse effects were nausea, diarrhea, gastroesophageal reflux, headache, and acneiform rash but there was no difference in their incidence between niacinamide and placebo. CONCLUSIONS: In conclusion, niacinamide is safe and well-tolerated in patients with ADPKD. However, we were unable to detect a sustained inhibition of sirtuin activity over 12 months of treatment, and there was no signal to suggest a beneficial effect on any efficacy measure.
引用
- El Ters M, Zhou X, Lepping RJ, et al. Biological Efficacy and Safety of Niacinamide in Patients With ADPKD. Kidney Int Rep. 2020. PMID: 32775826. doi:10.1016/j.ekir.2020.06.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。